The estimated Net Worth of James J Schutz is at least 117 千$ dollars as of 8 March 2018. James Schutz owns over 2,473 units of Sonoma Pharmaceuticals stock worth over 117,256$ and over the last 8 years James sold SNOA stock worth over 0$.
James has made over 7 trades of the Sonoma Pharmaceuticals stock since 2016, according to the Form 4 filled with the SEC. Most recently James bought 2,473 units of SNOA stock worth 9,867$ on 8 March 2018.
The largest trade James's ever made was buying 2,473 units of Sonoma Pharmaceuticals stock on 8 March 2018 worth over 9,867$. On average, James trades about 517 units every 38 days since 2016. As of 8 March 2018 James still owns at least 35,858 units of Sonoma Pharmaceuticals stock.
You can see the complete history of James Schutz stock trades at the bottom of the page.
James's mailing address filed with the SEC is C/O SONOMA PHARMACEUTICALS, INC., 1129 N. MCDOWELL BLVD., PETALUMA, CA, 94954.
Over the last 8 years, insiders at Sonoma Pharmaceuticals have traded over 0$ worth of Sonoma Pharmaceuticals stock and bought 25,155 units worth 125,359$ . The most active insiders traders include Frederick J Sandford、Sharon Barbari、Robert E Miller. On average, Sonoma Pharmaceuticals executives and independent directors trade stock every 27 days with the average trade being worth of 4,840$. The most recent stock trade was executed by Robert E Miller on 12 March 2018, trading 2,400 units of SNOA stock currently worth 9,744$.
sonoma pharmaceuticals, inc., develops and produces stabilized hypochlorous acid (hocl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions in the united states and internationally. the company offers epicyn, an antimicrobial facial cleanser; levicyn, a hypochlorous acid (hocl) based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; celacyn gel, a product indicated to promote healing through the management of new and old scars resulting from surgical procedures and trauma wounds or burns; sebuderm, a product indicated to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis; and ceramax, a lipogrid based skin barrier cream for management of dry itchy skin, minor skin irritations, rashes, and inflammation caused by various skin conditions, as well as loyon for the management of skin scal
Sonoma Pharmaceuticals executives and other stock owners filed with the SEC include: